Innate Immune Response Restarts Adaptive Immune Response in Tumors

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Oct 2

PMID 37781382

Authors

Wen-Shan Li

Qing-Qing Zhang

Qiao Li

Shang-Yu Liu

Guo-Qiang Yuan

Ya-Wen Pan

Affiliations

Soon will be listed here.

Abstract

The imbalance of immune response plays a crucial role in the development of diseases, including glioblastoma. It is essential to comprehend how the innate immune system detects tumors and pathogens. Endosomal and cytoplasmic sensors can identify diverse cancer cell antigens, triggering the production of type I interferon and pro-inflammatory cytokines. This, in turn, stimulates interferon stimulating genes, enhancing the presentation of cancer antigens, and promoting T cell recognition and destruction of cancer cells. While RNA and DNA sensing of tumors and pathogens typically involve different receptors and adapters, their interaction can activate adaptive immune response mechanisms. This review highlights the similarity in RNA and DNA sensing mechanisms in the innate immunity of both tumors and pathogens. The aim is to enhance the anti-tumor innate immune response, identify regions of the tumor that are not responsive to treatment, and explore new targets to improve the response to conventional tumor therapy and immunotherapy.

References

Lam K, Araya R, Huang A, Chen Q, Di Modica M, Rodrigues R . Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021; 184(21):5338-5356.e21. PMC: 8650838. DOI: 10.1016/j.cell.2021.09.019. View

Hu Z, Chai J . Assembly and Architecture of NLR Resistosomes and Inflammasomes. Annu Rev Biophys. 2023; 52:207-228. DOI: 10.1146/annurev-biophys-092922-073050. View

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Raghavan S, Mehta P, Xie Y, Lei Y, Mehta G . Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer. 2019; 7(1):190. PMC: 6642605. DOI: 10.1186/s40425-019-0666-1. View

Oettle H, Neuhaus P, Hochhaus A, Hartmann J, Gellert K, Ridwelski K . Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310(14):1473-81. DOI: 10.1001/jama.2013.279201. View

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

Stilp A, Scherer M, Konig P, Furstberger A, Kestler H, Stamminger T . The chromatin remodeling protein ATRX positively regulates IRF3-dependent type I interferon production and interferon-induced gene expression. PLoS Pathog. 2022; 18(8):e1010748. PMC: 9387936. DOI: 10.1371/journal.ppat.1010748. View

Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H . Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003; 301(5633):640-3. DOI: 10.1126/science.1087262. View

10.

Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Floter J . NFATc1 controls the cytotoxicity of CD8 T cells. Nat Commun. 2017; 8(1):511. PMC: 5593830. DOI: 10.1038/s41467-017-00612-6. View

11.

Kumar P, Sweeney T, Skabkin M, Skabkina O, Hellen C, Pestova T . Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5'-terminal regions of cap0-, cap1- and 5'ppp- mRNAs. Nucleic Acids Res. 2013; 42(5):3228-45. PMC: 3950709. DOI: 10.1093/nar/gkt1321. View

12.

Gay N, Gangloff M, ONeill L . What the Myddosome structure tells us about the initiation of innate immunity. Trends Immunol. 2011; 32(3):104-9. DOI: 10.1016/j.it.2010.12.005. View

13.

Chapuis A, Thompson J, Margolin K, Rodmyre R, Lai I, Dowdy K . Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012; 109(12):4592-7. PMC: 3311364. DOI: 10.1073/pnas.1113748109. View

14.

Gong W, Hoffmann J, Stock S, Wang L, Liu Y, Schubert M . Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. Cancer Immunol Immunother. 2019; 68(7):1195-1209. PMC: 11028180. DOI: 10.1007/s00262-019-02354-4. View

15.

Gao D, Li T, Li X, Chen X, Li Q, Wight-Carter M . Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci U S A. 2015; 112(42):E5699-705. PMC: 4620884. DOI: 10.1073/pnas.1516465112. View

16.

Sarhan J, Liu B, Muendlein H, Weindel C, Smirnova I, Tang A . Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ. 2018; 26(2):332-347. PMC: 6329789. DOI: 10.1038/s41418-018-0122-7. View

17.

Ghoneim H, Fan Y, Moustaki A, Abdelsamed H, Dash P, Dogra P . De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017; 170(1):142-157.e19. PMC: 5568784. DOI: 10.1016/j.cell.2017.06.007. View

18.

Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R . Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2013; 59(4):1415-26. PMC: 4139003. DOI: 10.1002/hep.26731. View

19.

Mullard A . FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017; 16(10):669. DOI: 10.1038/nrd.2017.196. View

20.

Wen H, Miao E, Ting J . Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity. 2013; 39(3):432-41. PMC: 3835203. DOI: 10.1016/j.immuni.2013.08.037. View